JPRN-jRCT2080223678已完成3 期
A phase 3 clinical trial of duloxetine in children and adolescents with depressive disorder
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 149
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 9age old 至 <= 17age old（—）
- 性别
- All
入选标准
- •Patients who diagnosed with major depressive disorder or persistent depressive disorder as defined by Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) and completely meet the criteria of major depressive episode. And et al.
排除标准
- •Patients who have allergies to two or more medicines or have a history of severe allergic reactions with medicines. Patients who have participated in a clinical study or a clinical investigation of duloxetine and have previously received study drugs. And et al.
研究者
相似试验
进行中（未招募）
1 期
MS-STAT2 - Multiple Sclerosis – Simvastatin Trial 2Multiple sclerosisEUCTR2017-003328-56-GBniversity College London Comprehensive Clinical Trials Unit1,180
进行中（未招募）
1 期
Pembrolizumab/placebo plus chemotherapy as first-line therapy in participants with HER2 negative advanced gastric or GEJ adenocarcinomaHER2 negative, previously untreated, unresectable or metastatic gastric or gastroesophageal junction adenocarcinomaMedDRA version: 21.1Level: LLTClassification code 10071114Term: Metastatic gastric adenocarcinomaSystem Organ Class: 100000004864MedDRA version: 21.0Level: LLTClassification code 10058526Term: Oesophageal adenocarcinoma metastaticSystem Organ Class: 100000004864EUCTR2018-001757-27-GBMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.1,542
进行中（未招募）
1 期
Pembrolizumab/placebo plus chemotherapy as first-line therapy in participants with HER2 negative advanced gastric or GEJ adenocarcinomaHER2 negative, previously untreated, unresectable or metastatic gastric or gastroesophageal junction adenocarcinomaMedDRA version: 27.0Level: LLTClassification code 10071114Term: Metastatic gastric adenocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 27.0Level: LLTClassification code 10058526Term: Oesophageal adenocarcinoma metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-001757-27-IEMerck Sharp & Dohme LLC1,542
进行中（未招募）
1 期
Pembrolizumab/placebo plus chemotherapy as first-line therapy in participants with HER2 negative advanced gastric or GEJ adenocarcinomaEUCTR2018-001757-27-ITMERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.1,542
进行中（未招募）
1 期
Pembrolizumab/placebo plus chemotherapy as first-line therapy in participants with HER2 negative advanced gastric or GEJ adenocarcinomaEUCTR2018-001757-27-HUMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.1,542